Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
|Articles|August 11, 2015
Self-Contained Laboratory Homogenizer Prepares Injectable Drugs
GEA's self-contained homogenizer is designed for laboratory applications, including cell dispersions.
GEA's Pony NS2006L is a self-contained, high-pressure laboratory and pilot plant homogenizer for product development of advanced fluid applications, including nanoparticles, nanodispersions, nanoemulsions, and cell dispersions. The homogenizers can reduce particle sizes down to nanometer range for the preparation of injectable drugs.
The homogenizer is designed for continuous operation up to 1500 bar. The sanitary design is suited for clean-in-place and sterilization-in-place. The Pony NS2006L achieves the same results as larger size homogenizers, and its compact design allows easy installation with simple operation and quick maintenance. It is also suitable for viscous products.
Source:
Related to this article
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
How to test pen injector assembly interfaces from URS to FAT and SAT: verify part tracking, reject confirmation, restarts, and data transfer evidence.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
3
Humanitas Global Health Launces at AAPS PharmSci 360 Event
4
AAPS PharmSci 360 2026: Roller-Compacted Formulations
5